Full Archive

Is this the same market?

Before I get into the earnings released by Insulet this afternoon here’s something to chew on. Tandem closed at $15.20 down another 14.37%. As it stands today this company with almost $500 million in cash and some 440,000 users has a market cap of …. Wait for it … $988 MILLION – think about that just for a moment boys and girls. And as you are about to see it’s...

This is NOT going to end well.

Looking over the results released by Tandem yesterday and reading through the earnings call transcript a few things stood out- 1. Tandem is almost like a teenager who gets caught in lie and then comes up with multiple explanations to explain away this lie. 2. The company is also trying to jump on the GLP-1 bandwagon and using clinical data to back up their assertion that increasing GLP-1 usage will help Tandem...

This is the way

It really isn’t enough to say once again we were spot on, and analysts were dead wrong. Momma Kliff didn’t like it when any of her children gloated preferring instead that our accomplishments stand on their own merit. Mom always said when you do a good job people will notice, when others screw up, they’ll notice that more and appreciate you more. Well, there is no question the analysts screwed...

The Floodgates are set to open.

Today we learned that Dexcom was among the investors in a Series B funding round for diabetes/obesity startup Signos. The Friday before Ilant Health a “new virtual provider targeting obesity treatment” launched with $3 million in funding. I’m pretty sure there are more that we missed but this is just the beginning. Get ready for investor money to start pouring into what we are calling the Ozempic Cost Containment (OCC)...

Exhibit One

Mark Twain once stated that reports of his demise have been greatly exaggerated. The same can be said for how sales of Ozempic and all the other GLP-1’s would impact sales of diabetes tech. We got our first set of facts toady when Abbott reported strong growth for sales of Libre. This really should not come as a surprise as once again we were right, and the analysts were wrong. We’ll...

Off the reservation

This is getting just a little no this getting way out of hand. Last week Novo Nordisk raised sales and profits estimates. The Washington Post publishes an article on how Ozempic is changing everything from food sales to the size of airline seats. Fans of Lady Gaga are calling her Ozempic Gaga given her recent weight loss. Industries and companies which aren’t remotely impacted by Ozempic are being impacted. The...

Swimming upstream

Years ago, Diabetic Investor felt alone in the wilderness when we were the only publication that came out against Exubera. Everyone and we do mean everyone thought this was going to be a multi-billion-dollar drug. That was everyone but us. We accurately predicted that Exubera would be a colossal failure heck we even said so on CNBC. We swam upstream again when all the analysts said no one would use Byetta...